KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2016 - 2025)

Jazz Pharmaceuticals has reported EBITDA Margin over the past 16 years, most recently at 21.25% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 372.0% year-over-year to 21.25%; the TTM value through Dec 2025 reached 6.84%, down 2147.0%, while the annual FY2025 figure was 10.08%, 2769.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 21.25% at Jazz Pharmaceuticals, up from 5.11% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 26.68% in Q1 2021 and troughed at 65.64% in Q2 2025.
  • A 5-year average of 5.19% and a median of 10.76% in 2022 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 6215bps in 2021 and later tumbled -8512bps in 2025.
  • Year by year, EBITDA Margin stood at 5.51% in 2021, then tumbled by -592bps to 27.09% in 2022, then skyrocketed by 145bps to 12.11% in 2023, then skyrocketed by 45bps to 17.53% in 2024, then grew by 21bps to 21.25% in 2025.
  • Business Quant data shows EBITDA Margin for JAZZ at 21.25% in Q4 2025, 5.11% in Q3 2025, and 65.64% in Q2 2025.